GlassScriptPhysician profile
Monique Canonico
NPI 1578619656
$7,993.45
in general payments reported to CMS, 2019-2025
23 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $612 · 2021: $568 · 2022: $912 · 2023: $1,742 · 2024: $1,304 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Consulting Fee: $300 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.96 |
| Consulting Fee | $300.00 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,023.48 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Emd Serono, INC. | $746.07 | 2021-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $577.60 | 2019-2023 | |
| Abbvie INC. | $539.98 | 2022-2025 | Botox |
| Genentech, INC. | $478.27 | 2022-2024 | Ocrevus, Enspryng, Activase |
| Eisai INC. | $443.44 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $365.47 | 2023-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $340.30 | 2019-2024 | Kisunla, Emgality |
| Allergan, INC. | $323.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $323.40 | 2019-2024 | Ajovy |
| Harmony Biosciences LLC | $313.11 | 2023-2025 | Wakix |
| Genentech USA, INC. | $222.06 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Xolair |
| Novartis Pharmaceuticals Corporation | $170.56 | 2019-2021 | |
| Livanova USA, INC. | $160.45 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $140.92 | 2021-2024 | Xeomin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $132.37 | 2019 | |
| Genzyme Corporation | $132.32 | 2020-2023 | |
| Tg Therapeutics, INC. | $125.46 | 2023 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2020 | |
| Lundbeck LLC | $121.22 | 2025 | Vyepti |
| Revance Therapeutics, INC. | $90.39 | 2025 | Daxxify |
| Celgene Corporation | $81.28 | 2019 | |
| Amgen INC. | $16.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Canonico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.